Biogen Idec and Elan enrol first patient in large, well-controlled head-to-head study of multiple sclerosis treatments

Biogen Idec and Elan Corp plc announced enrolment of the first patient in a global Phase IIIb, randomised, rater-blinded, active-controlled study designed to evaluate switching to Tysabri (natalizumab) from Copaxone [...]